Tea Soon Park1, Imran Bhutto, Ludovic Zimmerlin, Jeffrey S Huo, Pratik Nagaria, Diana Miller, Abdul Jalil Rufaihah, Connie Talbot, Jack Aguilar, Rhonda Grebe, Carol Merges, Renee Reijo-Pera, Ricardo A Feldman, Feyruz Rassool, John Cooke, Gerard Lutty, Elias T Zambidis. 1. Institute for Cell Engineering, and Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (T.S.P., L.Z., J.S.H., J.A., E.T.Z.); Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD (I.B., R.G., C.M., G.L.); Department of Radiation Oncology (P.N., F.R.) and Department of Microbiology/Immunology (D.M., R.A.F.), University of Maryland School of Medicine, Baltimore, MD; Department of Cardiovascular Medicine (A.J.R., J.C.) and Institute for Stem Cell Biology and Regenerative Medicine (A.J.R., R.R.-P., J.C.), Stanford University, Palo Alto, CA; and Institute for Basic Biomedical Science at Johns Hopkins School of Medicine, Baltimore, MD (C.T.).
Abstract
BACKGROUND: The generation of vascular progenitors (VPs) from human induced pluripotent stem cells (hiPSCs) has great potential for treating vascular disorders such as ischemic retinopathies. However, long-term in vivo engraftment of hiPSC-derived VPs into the retina has not yet been reported. This goal may be limited by the low differentiation yield, greater senescence, and poor proliferation of hiPSC-derived vascular cells. To evaluate the potential of hiPSCs for treating ischemic retinopathies, we generated VPs from a repertoire of viral-integrated and nonintegrated fibroblast and cord blood (CB)-derived hiPSC lines and tested their capacity for homing and engrafting into murine retina in an ischemia-reperfusion model. METHODS AND RESULTS: VPs from human embryonic stem cells and hiPSCs were generated with an optimized vascular differentiation system. Fluorescence-activated cell sorting purification of human embryoid body cells differentially expressing endothelial/pericytic markers identified a CD31(+)CD146(+) VP population with high vascular potency. Episomal CB-induced pluripotent stem cells (iPSCs) generated these VPs with higher efficiencies than fibroblast-iPSC. Moreover, in contrast to fibroblast-iPSC-VPs, CB-iPSC-VPs maintained expression signatures more comparable to human embryonic stem cell VPs, expressed higher levels of immature vascular markers, demonstrated less culture senescence and sensitivity to DNA damage, and possessed fewer transmitted reprogramming errors. Luciferase transgene-marked VPs from human embryonic stem cells, CB-iPSCs, and fibroblast-iPSCs were injected systemically or directly into the vitreous of retinal ischemia-reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice. Only human embryonic stem cell- and CB-iPSC-derived VPs reliably homed and engrafted into injured retinal capillaries, with incorporation into damaged vessels for up to 45 days. CONCLUSIONS: VPs generated from CB-iPSCs possessed augmented capacity to home, integrate into, and repair damaged retinal vasculature.
BACKGROUND: The generation of vascular progenitors (VPs) from human induced pluripotent stem cells (hiPSCs) has great potential for treating vascular disorders such as ischemic retinopathies. However, long-term in vivo engraftment of hiPSC-derived VPs into the retina has not yet been reported. This goal may be limited by the low differentiation yield, greater senescence, and poor proliferation of hiPSC-derived vascular cells. To evaluate the potential of hiPSCs for treating ischemic retinopathies, we generated VPs from a repertoire of viral-integrated and nonintegrated fibroblast and cord blood (CB)-derived hiPSC lines and tested their capacity for homing and engrafting into murine retina in an ischemia-reperfusion model. METHODS AND RESULTS: VPs from human embryonic stem cells and hiPSCs were generated with an optimized vascular differentiation system. Fluorescence-activated cell sorting purification of human embryoid body cells differentially expressing endothelial/pericytic markers identified a CD31(+)CD146(+) VP population with high vascular potency. Episomal CB-induced pluripotent stem cells (iPSCs) generated these VPs with higher efficiencies than fibroblast-iPSC. Moreover, in contrast to fibroblast-iPSC-VPs, CB-iPSC-VPs maintained expression signatures more comparable to human embryonic stem cell VPs, expressed higher levels of immature vascular markers, demonstrated less culture senescence and sensitivity to DNA damage, and possessed fewer transmitted reprogramming errors. Luciferase transgene-marked VPs from human embryonic stem cells, CB-iPSCs, and fibroblast-iPSCs were injected systemically or directly into the vitreous of retinal ischemia-reperfusion-injured adult nonobese diabetic-severe combined immunodeficientmice. Only human embryonic stem cell- and CB-iPSC-derived VPs reliably homed and engrafted into injured retinal capillaries, with incorporation into damaged vessels for up to 45 days. CONCLUSIONS: VPs generated from CB-iPSCs possessed augmented capacity to home, integrate into, and repair damaged retinal vasculature.
Authors: Maria B Grant; Sergio Caballero; Gary A J Brown; Steven M Guthrie; Robert N Mames; Timothy Vaught; Edward W Scott Journal: Adv Exp Med Biol Date: 2003 Impact factor: 2.622
Authors: Sahng Y Kim; Mary A Johnson; D Scott McLeod; Theresa Alexander; Barbara C Hansen; Gerard A Lutty Journal: Diabetes Date: 2005-05 Impact factor: 9.461
Authors: Sahng Y Kim; Mary A Johnson; D Scott McLeod; Theresa Alexander; Tsuyoshi Otsuji; Scott M Steidl; Barbara C Hansen; Gerard A Lutty Journal: Invest Ophthalmol Vis Sci Date: 2004-12 Impact factor: 4.799
Authors: Nilanjana Sengupta; Sergio Caballero; Robert N Mames; Jason M Butler; Edward W Scott; Maria B Grant Journal: Invest Ophthalmol Vis Sci Date: 2003-11 Impact factor: 4.799
Authors: Zsuzsanna H McMahan; Tricia R Cottrell; Fredrick M Wigley; Brendan Antiochos; Elias T Zambidis; Tea Soon Park; Marc K Halushka; Laura Gutierrez-Alamillo; Raffaello Cimbro; Antony Rosen; Livia Casciola-Rosen Journal: Arthritis Rheumatol Date: 2016-10 Impact factor: 10.995
Authors: Yosuke K Kurokawa; Rose T Yin; Michael R Shang; Venktesh S Shirure; Monica L Moya; Steven C George Journal: Tissue Eng Part C Methods Date: 2017-08 Impact factor: 3.056
Authors: Ludovic Zimmerlin; Tea Soon Park; Jeffrey S Huo; Karan Verma; Sarshan R Pather; C Conover Talbot; Jasmin Agarwal; Diana Steppan; Yang W Zhang; Michael Considine; Hong Guo; Xiufeng Zhong; Christian Gutierrez; Leslie Cope; M Valeria Canto-Soler; Alan D Friedman; Stephen B Baylin; Elias T Zambidis Journal: Development Date: 2016-09-22 Impact factor: 6.868
Authors: Valeria V Orlova; Francijna E van den Hil; Sandra Petrus-Reurer; Yvette Drabsch; Peter Ten Dijke; Christine L Mummery Journal: Nat Protoc Date: 2014-05-29 Impact factor: 13.491